tradingkey.logo

Secretome Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1 Study of STM-01 in Heart Failure with Preserved Ejection Fraction

ReutersMar 25, 2025 1:10 PM

-

  • SECRETOME THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN GROUNDBREAKING PHASE 1 STUDY OF STM-01 IN HEART FAILURE WITH PRESERVED EJECTION FRACTION

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI